PTC Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), Unrealized
PTC Therapeutics, Inc. (PTCT) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$458.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-07-30
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$1.34M.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was $887.00K.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was $1.39M, a 86.43% decline year-over-year.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $171.00K.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$3.38M, a 132.58% decline from fiscal 2024.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $10.37M, a 26.49% decline from fiscal 2023.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2023 was $14.11M.
- PTC Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$13.26M.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$458.00K 10-Q · filed 2026-07-30 | $930.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $887.00K 10-Q · filed 2026-05-07 | $2.27M derived: sum of 2 quarters · filed 2026-05-07 | $2.45M derived: sum of 3 quarters · filed 2026-05-07 | -$242.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.56M derived: sum of 2 quarters · filed 2026-02-19 | -$1.13M derived: sum of 3 quarters · filed 2026-07-30 | -$3.38M 10-K · filed 2026-02-19 |
| 2025-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.52M derived: sum of 2 quarters · filed 2026-07-30 | -$4.77M 10-Q · filed 2025-11-04 | $5.46M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$4.94M 10-Q · filed 2026-07-30 | $5.29M derived: sum of 3 quarters · filed 2026-07-30 | $5.24M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$2.25M 10-Q · filed 2026-05-07 | $7.98M derived: sum of 2 quarters · filed 2026-05-07 | $7.92M derived: sum of 3 quarters · filed 2026-05-07 | $8.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.18M derived: sum of 2 quarters · filed 2026-02-19 | $10.64M derived: sum of 3 quarters · filed 2026-02-19 | $10.37M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $416.00K derived: sum of 2 quarters · filed 2025-11-04 | $147.00K 10-Q · filed 2025-11-04 | $17.65M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $198.00K 10-Q · filed 2025-08-07 | $17.70M derived: sum of 3 quarters · filed 2026-02-19 | $979.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$269.00K 10-Q · filed 2025-05-06 | $17.24M derived: sum of 2 quarters · filed 2026-02-19 | $512.00K derived: sum of 3 quarters · filed 2026-02-19 | $3.79M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $17.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $781.00K derived: sum of 2 quarters · filed 2026-02-19 | $4.06M derived: sum of 3 quarters · filed 2026-02-19 | $14.11M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$16.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$13.45M derived: sum of 2 quarters · filed 2024-11-07 | -$3.39M 10-Q · filed 2024-11-07 | $54.59M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.33M 10-Q · filed 2024-08-08 | $71.31M derived: sum of 3 quarters · filed 2025-02-27 | $36.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $10.06M 10-Q · filed 2024-04-25 | $68.04M derived: sum of 2 quarters · filed 2025-02-27 | $33.15M derived: sum of 3 quarters · filed 2025-02-27 | -$1.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $57.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $23.10M derived: sum of 2 quarters · filed 2025-02-27 | -$11.13M derived: sum of 3 quarters · filed 2025-02-27 | -$13.26M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$34.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$69.11M derived: sum of 2 quarters · filed 2023-10-26 | -$71.25M 10-Q · filed 2023-10-26 | -$85.36M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$34.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$36.36M 10-Q · filed 2023-08-03 | -$50.47M derived: sum of 3 quarters · filed 2024-02-29 | -$67.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$2.13M 10-Q · filed 2023-04-27 | -$16.25M derived: sum of 2 quarters · filed 2024-02-29 | -$33.54M derived: sum of 3 quarters · filed 2024-02-29 | -$24.84M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$14.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$31.41M derived: sum of 2 quarters · filed 2024-02-29 | -$22.70M derived: sum of 3 quarters · filed 2024-02-29 | -$47.39M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$17.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$8.59M derived: sum of 2 quarters · filed 2022-10-27 | -$33.28M 10-Q · filed 2022-10-27 | -$3.38M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$15.98M 10-Q · filed 2022-08-04 | $13.92M derived: sum of 3 quarters · filed 2023-02-21 | $37.75M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$24.69M 10-Q · filed 2022-05-03 | $5.21M derived: sum of 2 quarters · filed 2023-02-21 | $29.04M derived: sum of 3 quarters · filed 2023-02-21 | $40.96M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $29.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $53.73M derived: sum of 2 quarters · filed 2023-02-21 | $65.66M derived: sum of 3 quarters · filed 2023-02-21 | $56.98M 10-K · filed 2023-02-21 |
| 2020-09-30 | $23.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $35.75M derived: sum of 2 quarters · filed 2021-10-28 | $27.08M 10-Q · filed 2021-10-28 | $38.90M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $11.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $3.25M 10-Q · filed 2021-07-29 | $15.07M derived: sum of 3 quarters · filed 2022-02-22 | $14.93M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$8.68M 10-Q · filed 2021-05-04 | $3.15M derived: sum of 2 quarters · filed 2022-02-22 | $3.01M derived: sum of 3 quarters · filed 2022-02-22 | $3.81M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $11.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $11.68M derived: sum of 2 quarters · filed 2022-02-22 | $12.48M derived: sum of 3 quarters · filed 2022-02-22 | $11.62M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $660.00K derived: sum of 2 quarters · filed 2020-10-29 | -$205.00K 10-Q · filed 2020-10-29 | -$1.12M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $803.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$62.00K 10-Q · filed 2020-08-05 | -$980.00K derived: sum of 3 quarters · filed 2021-02-25 | -$767.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$865.00K 10-Q · filed 2020-04-30 | -$1.78M derived: sum of 2 quarters · filed 2021-02-25 | -$1.57M derived: sum of 3 quarters · filed 2021-02-25 | -$2.11M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$918.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$705.00K derived: sum of 2 quarters · filed 2021-02-25 | -$1.24M derived: sum of 3 quarters · filed 2021-02-25 | $59.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$323.00K derived: sum of 2 quarters · filed 2019-10-30 | $977.00K 10-Q · filed 2019-10-30 | $1.07M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $764.00K 10-Q · filed 2019-08-06 | $859.00K derived: sum of 3 quarters · filed 2020-03-02 | $2.87M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.30M 10-Q · filed 2019-05-02 | $1.40M derived: sum of 2 quarters · filed 2020-03-02 | $3.41M derived: sum of 3 quarters · filed 2020-03-02 | $2.58M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.11M derived: sum of 2 quarters · filed 2020-03-02 | $1.28M derived: sum of 3 quarters · filed 2020-03-02 | $459.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $1.18M derived: sum of 2 quarters · filed 2018-11-05 | $364.00K 10-Q · filed 2018-11-05 | $563.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$828.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$1.65M 10-Q · filed 2018-08-07 | -$1.45M derived: sum of 3 quarters · filed 2019-03-01 | -$1.89M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$820.00K 10-Q · filed 2018-05-09 | -$621.00K derived: sum of 2 quarters · filed 2019-03-01 | -$1.06M derived: sum of 3 quarters · filed 2019-03-01 | -$2.02M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$239.00K derived: sum of 2 quarters · filed 2019-03-01 | -$1.20M derived: sum of 3 quarters · filed 2019-03-01 | -$1.20M 10-K · filed 2019-03-01 |
| 2016-09-30 | -$438.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$1.40M derived: sum of 2 quarters · filed 2017-11-02 | -$1.40M 10-Q · filed 2017-11-02 | -$1.40M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | -$963.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$963.00K 10-Q · filed 2017-08-09 | -$963.00K derived: sum of 3 quarters · filed 2018-03-06 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-06 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $0.00 10-K · filed 2018-03-06 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |